<DOC>
	<DOCNO>NCT02049164</DOCNO>
	<brief_summary>The purpose study determine effective dose dose range AR08 treatment VMS menopausal female .</brief_summary>
	<brief_title>Safety Efficacy Study AR08 Treatment Vasomotor Symptoms ( VMS )</brief_title>
	<detailed_description />
	<criteria>1 . Generally healthy female &gt; 40 year age body mass index ( BMI ) â‰¤ 40 ; 2 . Has undergone menopause define follow : At least 12 month spontaneous amenorrhea ; At least 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL ; At least 6 week postsurgical bilateral oophorectomy ( without hysterectomy ) ; 3 . Experience minimum 7 moderate severe hot flush per day 50 moderate severe hot flush per week 1 . Resting systolic blood pressure ( SBP ) &lt; 110 mmHg , rest diastolic blood pressure ( DBP ) &lt; 50 mm Hg , rest heart rate ( HR ) &lt; 60 beat per minute awake ; 2 . Subjects preexist orthostatic hypotension Screening ; 3 . Use oral estrogen , progestin , androgen , selective estrogen receptor modifier ( SERM ) contain drug product within 8 week prior Screening ; use transdermal hormone product within 8 week prior Screening ; use vaginal hormone product ( ring , cream , gel ) within 4 week prior Screening ; use intrauterine progestin within 8 week prior Screening ; use progestin implant estrogen injectables within 3 month prior Screening ; use estrogen pellet progestin injectables within 6 month prior Screening ; 4 . History daily usage ( least 28 days/month ) either follow month prior initiation Screening : Antihypertensives Prophylactic antimigraine medication</criteria>
	<gender>Female</gender>
	<minimum_age>41 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>AR08 , Vasomotor Symptoms</keyword>
</DOC>